NLS Pharmaceutics Announces Positive Results from Study KO-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward in Animal Models
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 15 2025
0mins
Source: PRnewswire
Mazindol's Potential in Addiction Treatment: NLS Pharmaceutics announced positive preclinical results for Mazindol, indicating its potential as a non-opioid treatment for fentanyl use disorder, which is critical given the opioid epidemic in the U.S.
Mechanism of Action and Market Expansion: The study highlights Mazindol's multi-target pharmacological profile that may reduce withdrawal symptoms and opioid reward, positioning it as a safer alternative to traditional therapies, with plans for market expansion beyond ADHD and narcolepsy.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
